Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of RP6530, a Novel PI3K δ/γ Dual Inhibitor Given in Combination With an Anti-PD-1 Therapy, Pembrolizumab in Adult Patients With Relapsed or Refractory cHL

NCT03471351 is registered in ClinicalTrials.gov with Rhizen Pharmaceuticals SA as lead sponsor.

NCT NCT03471351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03471351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of RP6530, a Novel PI3K δ/γ Dual Inhibitor Given in Combination With an Anti-PD-1 Therapy, Pembrolizumab in Adult Patients With Relapsed or Refractory cHL
Lead sponsor
Rhizen Pharmaceuticals SA
Phase
Phase 1
Overall status
Terminated
Start date
July 18, 2018
Completion date
February 13, 2019
Enrollment
2 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

classical hodgkin lymphoma